About the Authors

Peter J. Hotez

hotez@bcm.edu (PJH); younbeen.kim@rightfund.org (YK)

Affiliations RIGHT Fund, Seoul, Republic of Korea, Texas Children’s Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America

Kim Bush

Affiliations RIGHT Fund, Seoul, Republic of Korea, Life Sciences Partnerships, Bill & Melinda Gates Foundation, Seattle, Washington, United States of America

Andrin Oswald

Affiliations RIGHT Fund, Seoul, Republic of Korea, Life Sciences Partnerships, Bill & Melinda Gates Foundation, Seattle, Washington, United States of America

Glenn Rockman

Affiliations RIGHT Fund, Seoul, Republic of Korea, Adjuvant Capital, New York, New York, United States of America

In-taek Lim

Affiliations RIGHT Fund, Seoul, Republic of Korea, Korean Ministry of Health and Welfare (MOHW), Sejong, Republic of Korea

Youngmee Jee

Affiliations RIGHT Fund, Seoul, Republic of Korea, Center for Infectious Disease Research at the National Institute of Health, Korea Centers for Disease Control & Prevention (CDC), Osong, Republic of Korea

Chang Jin Moon

Affiliation RIGHT Fund, Seoul, Republic of Korea

Jerome H. Kim

Affiliation International Vaccine Institute (IVI), Seoul, Republic of Korea

Younbeen Kim

hotez@bcm.edu (PJH); younbeen.kim@rightfund.org (YK)

Affiliation RIGHT Fund, Seoul, Republic of Korea

Competing Interests

I have read the journal's policy and the authors of this manuscript have the following competing interests: GR has an interest in the financial success of two public health impact investment funds, Global Health Investment Fund I, LLC, and Adjuvant Global Health Technology Fund, LP, where he holds investment advisory roles. Both organizations may benefit from grant funding provided by the organizations described in this publication. Equally, both organizations may be disadvantaged by grant funding provided flowing to competing technologies.